Literature DB >> 27260332

Colorectal cancer care in elderly patients: Unsolved issues.

Thomas Aparicio1, Frederic Pamoukdjian2, Laurent Quero3, Sylvain Manfredi4, Philippe Wind5, Elena Paillaud6.   

Abstract

Colorectal cancers are common in elderly patients. However, cancer screening is poorly used after 75. Elderly patients form a heterogeneous population with specific characteristics. Standards of care cannot therefore be transposed from young to elderly patients. Tumour resection is frequently performed but adjuvant chemotherapy is rarely prescribed as there are no clearly established standards of care. In a metastatic setting, recent phase III studies have demonstrated that doublet front-line chemotherapy provided no survival benefit. Moreover, several studies have established the benefit of bevacizumab in association with chemotherapy. There is a lack of evidence for the efficacy of anti-epidermal growth factor antibodies in elderly patients. Geriatric assessments could help to select the adequate treatment strategy for individual patients. Geriatric oncology is now the challenge we have to face, and more specific trials are needed.
Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant therapy; Chemotherapy; Geriatric oncology; Radiotherapy; Targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 27260332     DOI: 10.1016/j.dld.2016.05.011

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

1.  Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.

Authors:  P-F Zhang; F Wen; J Zhou; J-X Huang; K-X Zhou; Q-J Wu; X-Y Wang; M-X Zhang; W-T Liao; Q Li
Journal:  Clin Transl Oncol       Date:  2019-05-06       Impact factor: 3.405

2.  Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database.

Authors:  Amandine Gouverneur; Pauline Claraz; Marine Rousset; Mickaël Arnaud; Annie Fourrier-Réglat; Antoine Pariente; Thomas Aparicio; Ghada Miremont-Salamé; Pernelle Noize
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

Review 3.  Capecitabine Plus Bevacizumab for Cardiac Metastasis of Sigmoid Colon Cancer: Case Report and Literature Review.

Authors:  Sawako Hiroi; Masashi Miguchi; Satoshi Ikeda; Hideki Nakahara; Katsunori Shinozaki; Takashi Nishisaka; Hiroyuki Egi; Toshiyuki Itamoto
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

4.  Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Authors:  T Aparicio; O Bouché; J Taieb; E Maillard; S Kirscher; P-L Etienne; R Faroux; F Khemissa Akouz; F El Hajbi; C Locher; Y Rinaldi; T Lecomte; S Lavau-Denes; M Baconnier; A Oden-Gangloff; D Genet; E Paillaud; F Retornaz; E François; L Bedenne
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

5.  Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis.

Authors:  Nicola de'Angelis; Capucine Baldini; Raffaele Brustia; Patrick Pessaux; Daniele Sommacale; Alexis Laurent; Bertrand Le Roy; Vania Tacher; Hicham Kobeiter; Alain Luciani; Elena Paillaud; Thomas Aparicio; Florence Canuï-Poitrine; Evelyne Liuu
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

6.  Associations of Postoperative Complications Assessed by Clavien-Dindo Classification and Comprehensive Complication Index with Long-Term Overall Survival in Elderly Patients after Radical CRC Resection.

Authors:  Dong Wang; Jinghui Zhang; Zhigang Bai; Yingchi Yang; Tingting Wang; Lan Jin; Jin Wang; Guocong Wu; Tiankuo Kou; Zhongtao Zhang
Journal:  Clin Interv Aging       Date:  2020-10-13       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.